chronic hepatitis B
Conditions
Interventions
the group of Telbivudine:LdT treatment (600 mg/day) from 28th. week of pregnancy until the delivery day, in case of confirmed CHB during pregnancy, they continued to use LdT after delivery according t
the group of anti-hepatis B immunoglobulin(HBIG):HBIG (200 IU dose once) was administered by intramuscular injection three times at the 28th., 32th., and 36th. gestational weeks.
Sponsors
the first Affiliated Hospital of Jinan University
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. The pregnant women had serum HBV DNA load higher than 6log10 copies/mL and positive serum HBsAg and HBeAg before the treatment; 2. Ultrasound measurements performed during the 2nd. trimester showed no structural anomalies of the fetus without threatened abortion; 3. No alcohol/ smoking abuse or history; 4. No hypertensive disorders and diabetes mellitus before pregnancy.
Exclusion criteria
Exclusion criteria: 1. The pregnant women had other viral diseases or complications (such as hepatitis A, C, D, E and HIV infection); 2. The pregnant women had serious hepatic diseases, liver cirrhosis and or hepatic carcinoma and so on; 3. other drugs (such as immunologic drugs,cytotoxic drugs or steroids) were taken during the period of pregnancy; 4. Husband with HBV infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum marker for heptitis B;the level of HBV-DNA;serum biochemical test;Biometric data of the fetus under the ultrasound measurement;biometric data of the newborn; | — |
Countries
China
Contacts
Public ContactYoupeng Chen
Department of Infectious Diseases, the first Affiliated Hospital of Jinan University
Outcome results
None listed